-3.05%
-3.09%
-6.02%
-35.74%
-30.47%
-21.03%
955.60%
AI Spotlight on CLDX
Company Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer.The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.
The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc.with exclusive rights to CDX-301 and CD40 ligand; and Yale University.Celldex Therapeutics, Inc.
was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Market Data
| Last Price | 24.49 |
| Change Percentage | -3.05% |
| Open | 25.36 |
| Previous Close | 25.26 |
| Market Cap ( Millions) | 1625 |
| Volume | 677748 |
| Year High | 53.18 |
| Year Low | 22.17 |
| M A 50 | 25.54 |
| M A 200 | 33.19 |
Financial Ratios
| FCF Yield | -9.76% |
| Dividend Yield | 0.00% |
| ROE | -21.49% |
| Debt / Equity | 0.39% |
| Net Debt / EBIDTA | 19.47% |
| Price To Book | 2.07 |
| Price Earnings Ratio | -10.54 |
| Price To FCF | -10.25 |
| Price To sales | 162.87 |
| EV / EBITDA | -9.3 |
News
- Jan -13 - Blueprint Medicines price target lowered by $11 at Wedbush, here's why
- Dec -19 - Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
- Nov -20 - Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
- Nov -11 - Celldex Therapeutics to Present at Upcoming Investor Conferences
- Nov -06 - Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
- Nov -06 - Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Nov -04 - Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market
- Oct -26 - Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
- Oct -25 - Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
- Sep -26 - CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
- Sep -25 - Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
- Sep -16 - Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
- Sep -12 - Celldex Therapeutics to Present at Upcoming Investor Conferences
- Aug -08 - Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
- Aug -08 - Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Jul -29 - Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
- Jul -16 - Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
- Jun -04 - Celldex Therapeutics to Present at Jefferies Healthcare Conference
- Jun -02 - Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
- May -27 - Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Novel Therapeutics
Expected Growth : 11.3 %
What the company do ?
Novel Therapeutics from Celldex Therapeutics, Inc. develops targeted immunotherapies to treat various cancers and inflammatory diseases.
Why we expect these perspectives ?
Celldex Therapeutics' Novel Therapeutics segment growth of 11.3% is driven by increasing adoption of CDX-0158, a promising treatment for chronic refractory gout, and CDX-1140, a novel immunotherapy for various cancers. Strong clinical trial results, strategic partnerships, and expanding pipeline contribute to the segment's growth momentum.
Celldex Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| Glembatumumab vedotin | An antibody-drug conjugate designed to treat various types of cancer, including melanoma and breast cancer. |
| Varlilumab | A monoclonal antibody designed to treat various types of cancer, including melanoma, lung cancer, and kidney cancer. |
| CDX-0159 | A monoclonal antibody designed to treat various types of cancer, including melanoma and breast cancer. |
| CDX-1140 | A monoclonal antibody designed to treat various types of cancer, including breast cancer and lung cancer. |
| CDX-527 | A monoclonal antibody designed to treat various types of cancer, including melanoma and breast cancer. |
Celldex Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
Celldex Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cancer and immunological disorders.
Bargaining Power Of Customers
Celldex Therapeutics, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative options for patients.
Bargaining Power Of Suppliers
Celldex Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment.
Threat Of New Entrants
Celldex Therapeutics, Inc. has a high threat of new entrants due to the growing demand for cancer and immunological disorder treatments and the presence of emerging biotech companies.
Intensity Of Rivalry
Celldex Therapeutics, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.59% |
| Debt Cost | 3.95% |
| Equity Weight | 99.41% |
| Equity Cost | 11.94% |
| WACC | 11.89% |
| Leverage | 0.59% |
Celldex Therapeutics, Inc. : Quality Control
Celldex Therapeutics, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| DNLI | Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, … |
| RYTM | Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is … |
| IONS | Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for … |
| FOLD | Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the … |
| PTCT | PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
PTC Therapeutics
A-Score
1-Year Total Return ->
🥈
Denali Therapeutics
A-Score
1-Year Total Return ->
🥉
Amicus Therapeutics
A-Score
1-Year Total Return ->
4
Rhythm Pharma
A-Score
1-Year Total Return ->
5
Celldex Therapeutics
A-Score
1-Year Total Return ->
6
